dissemination – Page 69 – Communicable Diseases Research

The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 A-a gradient acute lung injury acute respiratory distress addition allergic reaction alveolar macrophage alveolar pressure antiviral immunity Antwerp ARDS Belgium blinded Breastfeeding Bruges carbonate clinical clinician Confirmed COVID-19 infection control group Controlled trial COVID-19 COVID-19 pandemic defined Delta dissemination Effect element enrolled enrolment EudraCT ferritin level Ghent GM-CSF granulocyte-macrophage colony-stimulating factor High dose hospital Hypothesis hypoxic failure hypoxic respiratory failure Immune homeostasis inflammatory monocyte Inhaled Intervention intravenous invasive mechanical IWRS system leukine® lung malignancy mechanical ventilation mechanical ventilator Methylprednisolone number objective Open-label outcome oxygen Oxygenation paO2/fiO2 parameters Partial participant Participants Patient PF ratio pregnant primary endpoint progression of disease promote Protein protocol randomised randomised controlled trial randomization Randomized reached receive recruitment Registered Repair mechanisms replaced Respiratory failure Roeselare Sample size sargramostim SpO2 standard care Standard of care status Study protocol supplemental oxygen Support syndrome therapy treat Treatment Trial university ventilatory support Version website were excluded White blood cell
[DOI] 10.1186/s13063-020-04451-7 PMC 바로가기 [Article Type] Letter

Two Randomized Controlled Trials of Bacillus Calmette-Guérin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 ambulance service assistant Bacillus BCG BCG vaccination BCG-vaccine blinded Care Community Controlled COVID-19 COVID-19 infection COVID-19 pandemic cumulative Denmark dissemination elderly element facilitate HCW HCWs Health care Health care worker Health-care workers hospital Hospital admission hospitals incidence Intervention intervention group investigators Medicine NaCl Netherlands number objective outcome outcome assessor parallel group participant Patient physician Placebo placebo group placebo-controlled protocol randomised randomised controlled trial Randomized randomized trial recruitment reduce Registered registry Research Sample size status stratified Study protocol the placebo group Trial vaccination Vaccine website
[DOI] 10.1186/s13063-020-04389-w PMC 바로가기 [Article Type] Letter

Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 7-point ordinal scale accelerate activities activity acute respiratory syndrome adaptive addition administration Admission airway Akershus allocation sequence Analysis anticipated approach automatically baseline Biochemistry Biomarker blinded Blinding Blood C-reactive protein cardiac troponin Chloroquine clinical Clinical outcome Clinical practice clinical status clinical symptom collected condition coronavirus coronavirus disease COVID-19 Culture database Department disease dissemination early treatment element Endpoint examined excluded extracorporeal membrane oxygenation Good harmonization hepatic injury history hospital Hospital admission hospitalisation hospitalised hospitalised patient Hospitalized Hydroxychloroquine Hypothesis In-hospital include independent Inpatient intensive care intensive care unit International Conference Intervention intervention arm Invasive mechanical ventilation Laboratory marker Microbiology Mortality nasopharyngeal NEWS2 non-invasive ventilation Norway number Nurse objective open label Oropharyngeal Oropharyngeal sampling outcome oxygen participant Patient patients peptide Placebo polymerase chain polymerase chain reaction positive Practice Pragmatic pragmatic trial primary endpoint profile Prolonged Protein protocol QT interval randomisation randomised randomised controlled randomised controlled trial randomization Randomized Randomized controlled trial recruited recruitment Registered renal requiring supplemental oxygen resource responsible RT-PCR Safe Sample size SARS-CoV-2 SARS-CoV-2 viral load score secondary Seven standard care statistical analyses status Study protocol subjects Surveillance therapy transcriptase Treatment treatment allocation Trial Two-arm university use of hydroxychloroquine Viral load virological clearance viruses vital signs website
[DOI] 10.1186/s13063-020-04420-0 PMC 바로가기 [Article Type] Letter

Adding Colchicine to the Antiretroviral Medication – Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 added Adding anti-inflammatory effect Antibiotics anticipated antioxidant antioxidants antiretroviral blinded both group CDC center change Clinical course Clinical improvement Colchicine component Consensus Controlled COVID-19 COVID-19 infection COVID-19 patients digoxin dissemination dosage double blind double-blind study element enrolled equation estimate Final GFR glomerular filtration rate group help Hospital stay hospitalized COVID-19 patients hypersensitivity hypoxic in both group infected with COVID-19 Inflammation inflammatory disorders Inpatient interleukin-8 intubation invasive Iran Kaletra kidney transplant recipients Lopinavir/ritonavir lung Lung CT MDA mechanism Minerals Nasopharyngeal swab National number objective outcome oxidative stress Oxygenation pandemic parallel group participant pathologic pathway Patient patients percentage Pneumonia positive Prospective protocol QTc randomised randomised controlled trial randomization Randomized Rate Ratio receive recruited recruitment reducing reduction Registered RT -PCR Sample size serum creatinine status Tehran time tomography Trace element treat treated Treatment two group two groups Vitamin website WHO guideline with COVID-19
[DOI] 10.1186/s13063-020-04455-3 PMC 바로가기 [Article Type] Letter

Umbilical cord blood therapy to prevent progression of COVID-19 related pneumonia: a structured summary of a study protocol for a pilot randomised controlled trial

Letter

Published on 2020-06-042022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 24 hour acute COVID-19 administration Anti-inflammatory ARDS block Blood blood cell Cell cells clinical Clinical improvement control group Cord blood COVID-19 COVID-19 patients dissemination dose Efficacy element Estimated feasibility feasible hospitalised patient immunomodulatory properties infected with SARS-CoV-2 injection intravenous Melbourne, Australia moderate New number objective occur outcome participant Patient Placebo Pneumonia Prevent progression protocol randomised randomised controlled trial RCT recruit recruitment Registered registry Safety Sample size SARS-COV-2 infection sealed severe ARDS severe pneumonia Standard status stem cells Study protocol supportive care therapy Tolerability Total Treatment Trial Umbilical cord umbilical cord blood virus website
[DOI] 10.1186/s13063-020-04387-y PMC 바로가기 [Article Type] Letter

Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 active malignancy acute respiratory distress syndrome Administered administration age approval approved ARDS assessment automated Berlin blinded Cell cell suspension cellular changes in chronic liver disease class clinical Clinical diagnosis Clinical outcome clinical outcomes clinical trial comparator Compliance conducted control group Controlled trial COVID 19 COVID-19 COVID-19 pandemic declined defined described determine diagnosis of COVID-19 dissemination Donor Dose escalation driving Effect Efficacy element eligible Elizabeth enrolled ethics committee EudraCT excluded facilitate failure fixed dose hospital ICU incidence Inclusion increase in index individual information infusion intensive care unit Intervention Invasive mechanical ventilation investigator King’s College London London Mesenchymal stem cells Mesenchymal stromal cells MHRA moderate Mortality MSC MSCs NIHR number objective open label Other outcome pandemic PaO participant Patient patient population patients with ARDS PCR test PF ratio Phase 1 Phase 2 Placebo placebo-controlled protocol protocol amendment Public randomised randomised controlled trial REC receiving recruited recruitment repair reported Research respiratory Resuscitation Sample size secondary Secondary objective Secondary outcomes Serious Adverse Events severe ARDS single intravenous infusion SOFA solution Standard steering committee stratified stromal cell Study protocol Therapeutics therapy trauma Treatment Trial triple blinded Trust umbilical United Kingdom university Venous Thromboembolism Ventilation verbal Volume web-based randomisation system website WHO Withdrawal
[DOI] 10.1186/s13063-020-04416-w PMC 바로가기 [Article Type] Letter

A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 48 hour Admission allergic reaction anticipated application AST/ALT Bacterial infection Bacterial infections blinded block Breast feeding clinical clinical trial Combination concealed conducted Contraception Control COVID-19 COVID-19 patient criteria defined dependent on Desirable diagnostic Diaphragm dissemination dose double blind ECMO Efficacy Efficacy and safety element Endpoint evaluate extracorporeal membrane oxygenation failure female Germany Hospital stay Hydroxychloroquine IL-6-Rezeptor blockade Immunosuppression immunosuppressive therapy IMV independent Inflammation ingredient Injury Inpatient intensive care units interfere Invasive mechanical ventilation investigator investigators less life lung failure mechanical ventilation methotrexate NaCl NIV non-invasive ventilation number objective outcome parallel group parameters participant Participation Pathogenesis Patient patients PCT performed placebo-controlled trial Pneumonia polymerase chain positive Prednisolone produced progression proof protocol Pulmonary function pulmonary inflammation Quality of life randomisation randomised randomised controlled trial recruited reduce Registered respiratory Safe Sample size SARS-CoV-2 SARS-CoV2 SARS-CoV2 infection SAS severe COVID-19 Severe COVID-19 pneumonia Simultaneous single dose status stratified Study protocol sulfasalazine System the patient therapy Tocilizumab Treatment Trial trials Tuberculosis ULN unit Ventilation ventilator ventilator free day ventilator free days VFD Viral hepatitis website
[DOI] 10.1186/s13063-020-04447-3 PMC 바로가기 [Article Type] Letter

Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hour acute respiratory distress syndrome addition Administered Anakinra anti-IL-1 anti-IL-6 anti-IL-6 receptor antibody Bacterial Belgium binding blinded blockade Blood characterized chest X-ray chimeric clinical Clinical improvement Combination composed Coronavirus infection COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 patient CT scan death defined discharge dissemination dose drug Effectiveness element EudraCT excluded experimental arm factorial design Fungal infection hospital hospital discharge Hospitalized hospitals hypoxia hypoxic respiratory failure ICU IL-1 IL-6 IL-6 blockade IL-6 receptor interleukin 1 blockade interleukin 6 blockade Intravenous injection Invasive mechanical ventilation LDH lymphopenia mechanical ventilation non-invasive ventilation number objective on mechanical ventilation open label Open-label outcome oxygen Oxygenation paO2/fiO2 participant Participants Patient patients with COVID-19 Phase 3 primary end point protocol randomisation randomised randomised controlled trial randomization Randomized receive receptor recruited recruitment Registered response Sample size Serum ferritin siltuximab standard care Standard of care status Study protocol subcutaneous injection supplemental oxygen syndrome System systemic cytokine systemic cytokine release syndrome Tocilizumab treated Trial usual care was selected Web website
[DOI] 10.1186/s13063-020-04453-5 PMC 바로가기 [Article Type] Letter

Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 95% CI absence addition administration of hydroxychloroquine Admission aerosol-generating procedures allergy analyzed Anesthesia antibody approved ARMS assigned balanced randomization blind Cancer Cantabria carried CDC Cell Chemoprophylaxis clinical Clinical data clinically coated Committee comparator Comparator group computer-generated control group Controlled Controlled clinical trial Controlled trial coronavirus COVID COVID-19 criteria CURB current detect Determination disease dissemination double blind double-blind dropout rate Efficacy Efficacy and safety element ELISA kit Emergency Endocrine estimate Ethics Euroimmun Evidence evidence of Germany GRADE greater group Health Health authority health-care healthcare personnel Healthcare professional healthcare professionals heart heart failure help hematological high risk hospital Hydroxychloroquine hydroxychloroquine sulfate hygiene Hypothesis ICU IDT IgA IgG IgM and IgG immune immunodeficiency in vitro incidence include Infection inhibit intensive care unit Intervention investigator kidney lactation liver measure Measures Medicine Negative PCR neurological New York number observation period outcome participant PCR performed Personal protective equipment Placebo positive positive SARS-CoV-2 PCR positive serology Pregnancy presenting Prevalence Primary outcome probes product professional Prophylaxis Prospective PROTECT Protective protocol Psychiatric randomised randomised controlled trial randomization Randomized randomized trial RCT receive recruitment reduce reported responsible risk RT-PCR Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR sequence Seroconversion serological serology severity Significant single center single-center study social distancing Spain Spanish Standard Statistical power status Study protocol subject Support Symptom symptomatic and asymptomatic Tablet Takara Taking Tamoxifen Transmission Treatment two-tailed university Vaccine virus website while
[DOI] 10.1186/s13063-020-04400-4 PMC 바로가기 [Article Type] Letter